Hims & Hers Health, Inc. (HIMS) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HIMS, 22.02$ (piyasa değeri 5B) fiyatla Healthcare işi olan Hims & Hers Health, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 56/100 puan alıyor.
Son analiz: 9 Şub 2026Hims & Hers Health, Inc. (HIMS) Sağlık ve Boru Hattı Genel Bakışı
Hims & Hers Health is revolutionizing healthcare access with its multi-specialty telehealth platform, offering personalized wellness solutions and prescription medications directly to consumers. With a strong focus on convenience and affordability, HIMS is poised to capitalize on the growing demand for digital health services and expand its market share.
Yatırım Tezi
Hims & Hers Health presents a notable research candidate due to its strong growth trajectory and disruptive business model. The company's direct-to-consumer telehealth platform is capitalizing on the increasing demand for convenient and affordable healthcare solutions. With a gross margin of 75.0% and a focus on recurring revenue through subscription-based prescription services, Hims & Hers is demonstrating strong financial performance. The company's ability to expand its product offerings and attract new customers through targeted marketing campaigns positions it for continued growth. Furthermore, the increasing acceptance of telehealth and the company's strategic partnerships with wholesale partners create significant opportunities for market expansion. The company's P/E ratio is 38.95, reflecting investor confidence in its future earnings potential. As Hims & Hers continues to innovate and scale its platform, it is poised to deliver significant value to shareholders.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $5.05B reflects strong investor confidence in the company's growth potential.
- Gross Margin of 75.0% indicates efficient operations and strong pricing power.
- P/E ratio of 38.95 suggests investors are willing to pay a premium for HIMS's earnings, anticipating future growth.
- The company operates a multi-specialty telehealth platform, offering a wide range of services and products.
- Hims & Hers connects consumers directly to licensed healthcare professionals, providing convenient and accessible care.
Rakipler & Benzerleri
Güçlü Yönler
- Strong brand recognition and reputation.
- Proprietary telehealth platform.
- Subscription-based revenue model.
- Direct-to-consumer approach.
Zayıflıklar
- Reliance on marketing spend for customer acquisition.
- Limited physical presence.
- Regulatory risks associated with telehealth and prescription medications.
- Competition from established healthcare providers and other telehealth companies.
Katalizörler
- Ongoing: Continued expansion of product offerings and services.
- Ongoing: Increasing adoption of telehealth among consumers.
- Upcoming: Potential partnerships with major healthcare providers.
- Ongoing: Strategic marketing initiatives to drive customer acquisition.
Riskler
- Potential: Changes in regulations governing telehealth and online prescriptions.
- Potential: Increased competition from other telehealth providers.
- Ongoing: Reliance on third-party suppliers for products and medications.
- Potential: Data security breaches and privacy concerns.
- Ongoing: High marketing expenses impacting profitability.
Büyüme Fırsatları
- Expansion into New Markets: Hims & Hers has the opportunity to expand its services into new geographic markets, both domestically and internationally. By leveraging its telehealth platform and marketing expertise, the company can reach a wider customer base and drive revenue growth. The global telehealth market is projected to reach $55.6 billion by 2027, representing a significant opportunity for Hims & Hers to expand its reach and capture market share. Timeline: Ongoing.
- Introduction of New Product Lines: Hims & Hers can further expand its product offerings to address a wider range of health and wellness needs. By introducing new product lines, such as chronic disease management programs or specialized skincare solutions, the company can attract new customers and increase revenue per user. The market for personalized health and wellness products is growing rapidly, driven by increasing consumer awareness and demand for customized solutions. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Hims & Hers can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By partnering with established healthcare providers or acquiring complementary telehealth companies, Hims & Hers can accelerate its growth and enhance its competitive position. The market for telehealth acquisitions is active, with companies seeking to consolidate their market share and expand their service offerings. Timeline: Ongoing.
- Enhancement of Technology Platform: Hims & Hers can continue to invest in its technology platform to improve the user experience and enhance its service offerings. By incorporating new features, such as AI-powered personalized recommendations or virtual reality-based therapy programs, the company can differentiate itself from competitors and attract new customers. The market for telehealth technology is constantly evolving, with new innovations emerging regularly. Timeline: Ongoing.
- Increased Focus on Mental Health Services: Hims & Hers can capitalize on the growing demand for mental health services by expanding its offerings in this area. By providing access to licensed therapists and offering personalized mental health programs, the company can address a critical unmet need and drive revenue growth. The market for mental health services is experiencing significant growth, driven by increasing awareness and acceptance of mental health issues. Timeline: Ongoing.
Fırsatlar
- Expansion into new markets and product lines.
- Strategic partnerships and acquisitions.
- Increased focus on mental health services.
- Enhancement of technology platform.
Tehditler
- Changes in telehealth regulations.
- Increased competition from new entrants.
- Data security and privacy breaches.
- Negative publicity or product recalls.
Rekabet Avantajları
- Brand Recognition: Strong brand recognition and reputation in the direct-to-consumer telehealth market.
- Proprietary Technology Platform: User-friendly and scalable telehealth platform that connects consumers with healthcare professionals.
- Subscription-Based Revenue Model: Recurring revenue stream from prescription medications and ongoing care.
- Data and Personalization: Ability to leverage data to personalize treatment plans and product recommendations.
HIMS Hakkında
Founded in 2017, Hims & Hers Health, Inc. emerged with a vision to transform the healthcare landscape by providing accessible and convenient solutions for everyday health needs. Recognizing the challenges individuals face in accessing traditional healthcare, the company pioneered a direct-to-consumer telehealth platform that connects users with licensed healthcare professionals. Initially focused on addressing stigmatized conditions like hair loss and erectile dysfunction, Hims & Hers has expanded its offerings to encompass a comprehensive range of health and wellness categories, including skincare, mental health, and primary care. The company's evolution has been marked by a commitment to innovation and customer-centricity, leveraging technology to deliver personalized and affordable healthcare solutions. Today, Hims & Hers operates a robust platform that offers prescription medication, over-the-counter products, and ongoing care from healthcare providers. With a strong emphasis on discretion and convenience, the company has cultivated a loyal customer base and established itself as a leader in the rapidly growing telehealth market. Hims & Hers continues to expand its product offerings and services, solidifying its position as a comprehensive digital health destination. The company's headquarters are located in San Francisco, California, and it serves customers across the United States.
Ne Yaparlar
- Connect consumers with licensed healthcare professionals through a telehealth platform.
- Offer prescription medication for various health conditions.
- Provide over-the-counter drug and device products.
- Offer cosmetics and supplement products.
- Focus on wellness, sexual health, skincare, and hair care.
- Provide medical consultation services.
- Offer health and wellness products through wholesale partners.
İş Modeli
- Direct-to-consumer sales of prescription and non-prescription products through their website and mobile app.
- Subscription-based recurring revenue for prescription medications and ongoing care.
- Revenue from medical consultation services provided by licensed healthcare professionals.
- Wholesale partnerships to distribute health and wellness products through other retailers.
Sektör Bağlamı
The telehealth industry is experiencing rapid growth, driven by increasing demand for convenient and affordable healthcare solutions. The market is characterized by intense competition, with companies vying for market share by offering innovative services and products. Hims & Hers Health is well-positioned to capitalize on this trend, leveraging its direct-to-consumer platform and comprehensive range of health and wellness offerings. The company faces competition from established healthcare providers and other telehealth companies, but its focus on personalized care and discreet service provides a competitive edge. The telehealth market is projected to continue its growth trajectory, creating significant opportunities for Hims & Hers to expand its market share and solidify its position as a leader in the industry.
Kilit Müşteriler
- Individuals seeking convenient and affordable access to healthcare.
- Consumers looking for solutions to address specific health conditions, such as hair loss, erectile dysfunction, and skincare concerns.
- People seeking personalized health and wellness products and services.
- Customers who value discretion and privacy in their healthcare experience.
Finansallar
Grafik & Bilgi
Hims & Hers Health, Inc. (HIMS) hisse senedi fiyatı: $22.02 (-2.14, -8.86%)
Son Haberler
-
EXCLUSIVE: Top 12 Most-Searched Tickers On Benzinga Pro In March – Where Do Tesla, Nvidia, Micron Stocks Rank?
benzinga · 2 Nis 2026
-
Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
Zacks · 26 Mar 2026
-
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
Yahoo! Finance: HIMS News · 23 Mar 2026
-
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
benzinga · 23 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
HIMS için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $20.19
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, HIMS'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
EXCLUSIVE: Top 12 Most-Searched Tickers On Benzinga Pro In March – Where Do Tesla, Nvidia, Micron Stocks Rank?
Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
En Son Hims & Hers Health, Inc. Analizi
Hims & Hers Surges 40.79% on Weight-Loss Drug Deal, AZI Skyrockets 146.40%
3 dakika okumaCyclical Value Stocks in Focus as ODFL Drops 7.93%, EONR Jumps 9.84%
4 dakika okumaPapa John's Surges 3.70% Amid Resurgence of 'Pentagon Pizza' Theory
2 dakika okumaPayPal Gains 5.76% Amid Acquisition Rumors, Novo Nordisk Plunges 16.43%
3 dakika okumaTech Sector Weakness Drags on Market, QQQ Down 1.44%
3 dakika okumaHims & Hers Health, Inc. Hissesi: Cevaplanan Temel Sorular
HIMS için değerlendirilmesi gereken temel faktörler nelerdir?
Hims & Hers Health, Inc. (HIMS) şu anda yapay zeka skoru 56/100, orta puanı gösteriyor. Hisse 38.9x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) üzerinde, yüksek büyüme beklentilerine işaret ediyor. Analist hedefi $20.19 ($22.02'dan -8%). Temel güçlü yan: Strong brand recognition and reputation.. İzlenmesi gereken birincil risk: Potential: Changes in regulations governing telehealth and online prescriptions.. Bu bir finansal tavsiye değildir.
HIMS MoonshotScore'u nedir?
HIMS şu anda MoonshotScore'da 56/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
HIMS verileri ne sıklıkla güncellenir?
HIMS fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler HIMS hakkında ne diyor?
Analistler, HIMS için $20.19 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($22.02) aşağı yönlü %8 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
HIMS'a yatırım yapmanın riskleri nelerdir?
HIMS için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Changes in regulations governing telehealth and online prescriptions.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
HIMS'ın P/E oranı nedir?
Hims & Hers Health, Inc. (HIMS)'nın son P/E oranı 38.9, ki bu da piyasa ortalamasının üzerinde, bu da yüksek büyüme beklentilerini gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
HIMS aşırı değerli mi, yoksa düşük değerli mi?
Hims & Hers Health, Inc. (HIMS)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 38.9. Analist hedefi $20.19 (mevcut fiyattan -8%), analistlerin hisse senedini adil değere yakın gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
HIMS'ın temettü verimi nedir?
Hims & Hers Health, Inc. (HIMS) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- Investment decisions should be made based on individual risk tolerance and financial circumstances.